Processing...
Clinical Trials for Prostate Cancer
Search
Search
There are 228 active trials for advanced/metastatic prostate cancer.
Click on a trial to see more information.
228 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Men with localized, histologically confirmed intraprostatic recurrence after prior external-beam or HDR brachytherapy (ECOG 0–1, no nodal/metastatic disease) undergo interstitial photodynamic therapy using the SpectraCure P18 laser with IDOSE planning plus verteporfin. Verteporfin is a benzoporphyrin photosensitizer that accumulates in tumor/neovasculature and, when light-activated, generates reactive oxygen species to induce vascular shutdown and tumor necrosis; patients unsuitable for salvage surgery or curative re-irradiation are eligible.
ClinicalTrials.gov ID: NCT03067051
TrialFetch AI summary: Men with metastatic castration‑resistant prostate cancer (ECOG 0–1) after at least one standard mCRPC therapy receive fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of autologous PSMA‑targeted CAR T cells (TmPSMA‑02). The CAR uses a humanized J591 scFv with CD2/CD3ζ signaling and dual “armor” (dominant‑negative TGF‑βRII and PD1–CD28 switch receptor) to enhance activity and overcome immunosuppression.
ClinicalTrials.gov ID: NCT06046040
TrialFetch AI summary: Adults with metastatic castration-resistant prostate cancer (adenocarcinoma or neuroendocrine variants), ECOG 0–1, are enrolled to receive a STEAP2-targeted theranostic: imaging with radiolabeled AZD2287 (± cold antibody AZD2275 pre-dose) followed by dose-escalated [225Ac]-AZD2284, an actinium-225–labeled anti-STEAP2 monoclonal antibody delivering alpha radiation to STEAP2-expressing tumors. Key exclusions include recent radiopharmaceuticals/therapy and significant comorbidities; outcomes focus on safety, dosimetry, biodistribution, and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT06879041
TrialFetch AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
TrialFetch AI summary: Adults with advanced/metastatic solid tumors who have exhausted standard options receive IV TJ101, a bispecific EGFR/B7-H3 antibody–drug conjugate, every 3 weeks in dose escalation with biomarker-driven expansion cohorts. Excludes prior topoisomerase I inhibitor or TOP1i-ADC exposure, active ILD/pneumonitis, significant ocular or uncontrolled cardiovascular disease, and active CNS disease unless treated and stable.
ClinicalTrials.gov ID: NCT07181473
TrialFetch AI summary: Adults with previously treated, locally advanced/metastatic small cell lung cancer or other neuroendocrine tumors (e.g., LCNEC, NEPC, high‑grade GI‑NET, Merkel cell) receive BL‑M14D1, an investigational DLL3‑targeted antibody–drug conjugate with a topoisomerase I inhibitor payload, given IV every 21 days. Suitable for ECOG 0–1 patients post‑standard therapy (SCLC requires prior platinum); excludes prior topo‑I ADCs, significant cardiac/QTc issues, ILD/pneumonitis, active CNS disease, and uncontrolled infections.
ClinicalTrials.gov ID: NCT07080242
TrialFetch AI summary: Adults with metastatic castration‑resistant prostate adenocarcinoma (ECOG 0–1) after progression on ADT receive AZD6621 monotherapy, a multispecific T‑cell–engaging antibody targeting STEAP2 on tumor cells and CD3/CD8 to preferentially activate CD8+ T cells; two administration routes are explored with dose escalation and expansion. Key exclusions include significant cardiac disease/QT prolongation, uncontrolled autoimmune disease, prior severe CRS/ICANS, active CNS disease, and recent cellular therapy.
ClinicalTrials.gov ID: NCT07192614
TrialFetch AI summary: Adults with metastatic castration‑resistant prostate adenocarcinoma (ECOG 0–1) with documented progression and adequate organ function receive AZD0516, a STEAP2‑targeted antibody–drug conjugate delivering an exatecan topoisomerase I inhibitor, either as monotherapy or combined with AZD9574 (palacaparib), a selective PARP1 inhibitor. Requires available tumor tissue; excludes prior STEAP2‑targeted therapy and significant CNS, pulmonary, infectious, or cardiovascular comorbidities.
ClinicalTrials.gov ID: NCT07181161
TrialFetch AI summary: Adult men with metastatic castration-resistant prostate cancer after at least one AR pathway inhibitor, ECOG 0–1, receive oral KTX-2001 (first-in-class NSD2 histone methyltransferase inhibitor targeting H3K36me2) as monotherapy or combined with darolutamide 600 mg BID. Excludes unstable CNS disease and significant cardiac/infection risks; aims to establish safety, PK/PD, and preliminary activity to define MTD/RP2D.
ClinicalTrials.gov ID: NCT07103018
TrialFetch AI summary: Adults with DLL3-expressing advanced solid tumors, including previously treated SCLC or LCNEC (dose escalation) and expansion cohorts of SCLC (≤2 prior lines), de novo or treatment-emergent NEPC, and GEP-NEC; some cohorts require demonstrable uptake on 111In-ETN029 SPECT. Single-arm therapy with 225Ac-ETN029, a DLL3-targeted alpha-emitting radiopharmaceutical delivering actinium-225 to tumor cells, with optional 111In-ETN029 imaging/dosimetry.
ClinicalTrials.gov ID: NCT07006727